Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy.
about
The Biochemistry and Epigenetics of Epilepsy: Focus on Adenosine and GlycineFrom unwitnessed fatality to witnessed rescue: Pharmacologic intervention in sudden unexpected death in epilepsyRole of adenosine in status epilepticus: a potential new target?Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsyAnticonvulsant activity of B2, an adenosine analog, on chemical convulsant-induced seizuresAdenosine Kinase Deficiency in the Brain Results in Maladaptive Synaptic Plasticity.Focused ultrasound-mediated suppression of chemically-induced acute epileptic EEG activity.Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.Increased cortical extracellular adenosine correlates with seizure terminationAdenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activityMethylxanthines, seizures, and excitotoxicity.Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets?Modulators of nucleoside metabolism in the therapy of brain diseases.Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.Purines and the Anti-Epileptic Actions of Ketogenic Diets.Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activityComorbidities in Neurology: Is adenosine the common link?Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies.Adenosine dysfunction in epilepsy.Adenosine, glutamate and pH: interactions and implications.Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activityGlycine transporter 1 is a target for the treatment of epilepsy.Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.The adenosine kinase hypothesis of epileptogenesisAdenosine-based cell therapy approaches for pharmacoresistant epilepsies.Silk polymer-based adenosine release: therapeutic potential for epilepsy.Glial adenosine kinase--a neuropathological marker of the epileptic brain.Adenosine dysfunction in astrogliosis: cause for seizure generation?The kainic acid model of temporal lobe epilepsyAdenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.Antiepileptic effects of silk-polymer based adenosine release in kindled rats.Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cellsNovel approaches to epilepsy treatment.Adenosine receptors and epilepsy: current evidence and future potential.Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological InterventionsAdenosine prevents kindled seizures--an effect as smooth as silk.Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants.Targeting the brain: focal delivery of natural anticonvulsant molecules.Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade
P2860
Q26752724-391C753B-B896-43CC-9282-3775E9D3A721Q26770025-008EE980-8290-4242-9B37-AAC7D4170414Q26991984-BFF40D10-6605-414E-814E-D1BD2871FDB4Q28259250-BC6D743B-E4EA-4769-8BBF-5A1EE548B47EQ28534300-1183270C-7B32-4D22-A5DC-D3F347DBA49DQ30355611-9760E88F-354C-4899-884F-F0392A0F5410Q30476237-C4FF248D-6E06-4EB0-AAF4-BE6F4969D5E1Q30541877-D9F5F374-82B5-4E64-B8E7-81110BA09779Q30605561-C8665F15-8957-4E35-B7E3-397A47B69C1FQ33924247-D3B7EB49-7479-4FD7-B7BE-26974B4C4AAAQ34101256-CF76D189-97CD-459A-90A3-4CBBB712E51AQ34154555-FDFC4211-4863-47A4-B19E-B56A535287FCQ34777954-2334B2A0-299F-40A1-BE2C-6A8BD7288670Q34842250-4FE1A214-CCCE-4C1F-B718-E5287056A9C1Q34997511-94296D20-DC76-4707-AF83-3027A7DFDE00Q35513799-82C59489-0A2E-440F-962F-2BCC3678B2D5Q35924978-CE68CF73-C160-47C3-A0D7-D4E113E97364Q35956389-48C247CA-5EEE-4DBB-8E3F-ECC461495D59Q35999731-5835347B-226A-4EC8-A0A1-85E467B99C94Q36036212-052B543C-5239-4302-A6F0-3AFBB6930746Q36097326-1E81C766-CA84-4E8D-BFF1-6E94EF4474ECQ36294092-01F4877E-CAB2-4030-84E2-D86D6B52F9E5Q36304849-8C9A9AD0-6D2C-4D7A-9B47-773F72C415A5Q36391066-1B17CF15-9011-4D90-9AB9-751BD7759DD2Q36515651-C5842F9E-4601-4C70-AB7C-34661CE8900DQ36788952-4D96DEF5-58DB-4BC5-A695-27E8677A6A65Q36819103-F4F4B49A-8D5B-41C2-9F26-57D8EF432B20Q36912637-FA6E2579-8618-4B4C-8D71-3CA393247A7DQ36923994-9D9F911E-0DC0-4F06-987B-AF04F18D42BAQ36932137-4325CCE2-9735-4CA6-9399-E04865508A0BQ37269991-2D4B224A-A628-4451-BB24-71DFD8306790Q37310106-75169A70-3BF7-411F-8C97-2CA5B3DD2D9DQ37426965-41D4F283-AE9A-4156-B1AA-FFECE1625350Q38056185-0FFEF856-8F7F-4FA3-A1CC-10BD065BB48FQ38245140-2BC321D9-A8F8-437F-937A-B0CA4AB47EA6Q38544300-9CA4836C-DFE3-44FC-855B-AAC0A434FDD5Q39553867-86084359-BA7E-4E0A-BC94-8C6F69FFDC84Q40390719-B3906B58-D37A-46BA-AA2F-80870D9FBA2EQ40579087-7EA6A6E4-BC00-492C-9BDE-37AAA61AB1B4Q40722338-DDDD759A-6716-4CA8-9085-86445FD94925
P2860
Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@en
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@nl
type
label
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@en
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@nl
prefLabel
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@en
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@nl
P1433
P1476
Seizure suppression by adenosi ...... of pharmacoresistant epilepsy.
@en
P2093
Nicolette Gouder
P2860
P304
P356
10.1046/J.1528-1157.2003.03603.X
P577
2003-07-01T00:00:00Z